|
|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblasto
|
1R01CA190121-01
|
$332,000
|
$109,560
|
VERHAAK, ROELAND
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia
|
1R21CA190028-01
|
$203,580
|
$203,580
|
BONETTO, ANDREA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL
|
1R01CA184922-01
|
$553,684
|
$276,842
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
|
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
|
5R21CA180097-02
|
$192,409
|
$192,409
|
DITTMER, DIRK
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers
|
1R01CA184968-01
|
$509,161
|
$254,581
|
SIKIC, BRANIMIR
|
STANFORD UNIVERSITY
|
|
|
(PQD5) Avatar-directed Treatment for Ovarian Cancer
|
1R01CA184502-01
|
$621,606
|
$621,606
|
HALUSKA, PAUL
|
MAYO CLINIC ROCHESTER
|
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
1R01CA185353-01
|
$405,890
|
$405,890
|
SHARPLESS, NORMAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
00000000; D.GUY; SEVERABLE OPERATIONS FOR NCI-FREDERICK
|
261200800001E
|
$296,673,020
|
$611
|
Heimbrook, David
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
|
2014 DNA Damage, Mutation and Cancer Gordon Research Conference
|
1R13CA183096-01
|
$5,000
|
$5,000
|
HANAWALT, PHILIP
|
GORDON RESEARCH CONFERENCES
|
|
|
2014 DNA Topoisomerases in Biology and Medicine Gordon Research Conference
|
1R13CA186371-01
|
$5,000
|
$5,000
|
BJORNSTI, MARY-ANN
|
GORDON RESEARCH CONFERENCES
|
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
|
5R44CA132257-04
|
$522,886
|
$522,886
|
MORGAN, LEE
|
DEKK-TEC, INC.
|
|
|
A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC
|
5R01CA157409-03
|
$607,647
|
$607,647
|
HOLLEN, PATRICIA
|
UNIVERSITY OF VIRGINIA
|
|
|
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors
|
2R42CA156930-02
|
$534,844
|
$534,844
|
JONES, BARRY
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
A Multidisciplinary and Translational Approach to Hepatobiliary Malignancy
|
5K24CA139570-05
|
$140,411
|
$140,411
|
NELSON, DAVID
|
UNIVERSITY OF FLORIDA
|
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
2R44CA159843-02
|
$748,921
|
$748,921
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
|
A Novel Agent with Dual Functions to Treat Head and Neck Cancer
|
1R21CA176032-01A1
|
$206,190
|
$206,190
|
TOBACK, FREDERICK
|
UNIVERSITY OF CHICAGO
|
|
|
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection
|
1R01CA183074-01A1
|
$335,113
|
$335,113
|
YUAN, ZHI-MIN
|
HARVARD SCHOOL OF PUBLIC HEALTH
|
|
|
A Phase I Study of CED of Liposomal-Irinotecan using imaging in High Grade Glioma
|
1R21CA186140-01
|
$324,935
|
$324,935
|
BUTOWSKI, NICHOLAS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
1R44CA183316-01
|
$190,601
|
$190,601
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
|
A protein based strategy to reverse bone marrow failure resulting from radiation
|
1R43CA186507-01A1
|
$224,738
|
$56,185
|
JIANG, XUN
|
MARROWSOURCE THERAPEUTICS INTERNATIONAL
|
|
|
A radiotherapeutic for breast cancer brain metastases
|
1R21CA187528-01
|
$202,275
|
$202,275
|
MAKALE, MILAN
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
A randomized trial of topical menthol for chemotherapy induced neuropathy
|
1R03CA181909-01A1
|
$69,600
|
$69,600
|
HERSHMAN, DAWN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer
|
7R01CA164447-04
|
$248,800
|
$248,800
|
BROWN, KATHLYNN
|
SRI INTERNATIONAL
|
|
|
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer
|
5R01CA164447-03
|
$115,937
|
$115,937
|
BROWN, KATHLYNN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
5R01CA168900-03
|
$322,040
|
$161,020
|
POWELL, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy
|
5R01CA169519-02
|
$290,754
|
$290,754
|
SALVEMINI, DANIELA
|
SAINT LOUIS UNIVERSITY
|
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
5K08CA160660-04
|
$156,330
|
$78,165
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-38S1
|
$74,997
|
$3,750
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-38
|
$7,449,701
|
$372,485
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Action of RB Pathway in Breast Cancer Therapy
|
3R01CA129134-05S1
|
$66,726
|
$66,726
|
KNUDSEN, ERIK
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Action of RB Pathway in Breast Cancer Therapy
|
5R01CA129134-05
|
$310,426
|
$310,426
|
KNUDSEN, ERIK
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Activating Bax as a therapeutic strategy for lung cancer
|
5R01CA175003-02
|
$300,653
|
$300,653
|
LI, CHI
|
UNIVERSITY OF LOUISVILLE
|
|
|
Acupuncture to Prevent Chemotherapy Dose Reduction
|
7R21CA173263-03
|
$184,886
|
$184,886
|
BAO, TING
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Adaptable Polymer Micelles for Tumor Targeting
|
5R01CA129287-05
|
$289,877
|
$289,877
|
PARK, KINAM
|
PURDUE UNIVERSITY WEST LAFAYETTE
|
|
|
Adaptive signaling exposes a therapeutic vulnerability in NRAS melanomas
|
1R21CA182020-01
|
$206,190
|
$103,095
|
WEBER, MICHAEL
|
UNIVERSITY OF VIRGINIA
|
|
|
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu
|
1U54CA190152-01
|
$697,934
|
$146,566
|
GOPAL, SATISH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Adoption and Retooling of GEM model for Pancreatic Cancer
|
ZIA BC 011463
|
$56,483
|
$39,538
|
Van Dyke, Terry
|
CCR (NCI)
|
|
|
Adult Brain Tumor Consortium (ABTC)
|
2UM1CA137443-06
|
$1,999,278
|
$1,999,278
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Aerobic Training During or After Adjuvant Therapy: A Randomized Trial
|
7R01CA164751-03
|
$547,430
|
$273,715
|
JONES, LEE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
3U01CA121947-08S1
|
$6,300,000
|
$6,300,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
AIDS Malignancy Clinical Trials Consortium (AMC)
|
5U01CA121947-08
|
$1,900,000
|
$1,900,000
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
ALL therapy and developing brains: MRI measures, genetic factors and cognition
|
5R01CA090246-09
|
$368,817
|
$368,817
|
REDDICK, WILBURN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
|
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer
|
1R01CA182832-01
|
$323,700
|
$323,700
|
MATEI, DANIELA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
|
Analysis of Anti-Cancer Chemicals and Pharmaceutical Formulations
|
N02CM120027-007
|
$15,008
|
$15,008
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE
|
|
|
Analysis of Anti-Cancer Chemiclas & Pharmaceutical Formulations
|
N02CM120026-008
|
$40,822
|
$40,822
|
WHITE, JONATHAN
|
MRIGLOBAL
|
|
|
Androgen Receptor in Bladder Cancer
|
ZIA BC 011527
|
$44,135
|
$8,827
|
Agarwal, Piyush
|
CCR (NCI)
|
|
|
Angiogenesis-targeting therapy for glioblastoma
|
5R01CA129371-07
|
$361,430
|
$180,715
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
|
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
|
5R21CA178344-02
|
$155,521
|
$155,521
|
ARMENIAN, SARO
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Anti-Migration Therapy for Prevention and Treatment of Breast Tumor
|
5R01CA160271-04
|
$314,201
|
$157,101
|
TANAKA, TAKEMI
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
|
Anti-PV1 Therapy for Pancreatic Cancer
|
5R21CA172983-02
|
$170,890
|
$170,890
|
STAN, RADU
|
DARTMOUTH COLLEGE
|
|
Total relevant funding to Chemotherapy for this search: $278,101,806
|
